V
Vincent J. Sullivan
Researcher at Research Triangle Park
Publications - 8
Citations - 544
Vincent J. Sullivan is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Anthrax vaccines & Adjuvant. The author has an hindex of 7, co-authored 8 publications receiving 513 citations.
Papers
More filters
Journal ArticleDOI
Protective Immunization against Inhalational Anthrax: A Comparison of Minimally Invasive Delivery Platforms
John A. Mikszta,Vincent J. Sullivan,Cheryl H. Dean,Andrea M. Waterston,Jason B. Alarcon,John P. Dekker,John M. Brittingham,Juan Huang,C. Robin Hwang,Matthew S. Ferriter,Ge Jiang,Kevin D. Mar,Kamal U. Saikh,Bradley G. Stiles,Chad J. Roy,Robert G. Ulrich,Noel G. Harvey +16 more
TL;DR: It is demonstrated, for the first time, that cutaneous or nasal mucosal administration of rPA provides complete protection against inhalational anthrax in rabbits.
Journal ArticleDOI
A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats
Juan Huang,Robert J. Garmise,Timothy M. Crowder,Kevin D. Mar,C. Robin Hwang,Anthony J. Hickey,John A. Mikszta,Vincent J. Sullivan +7 more
TL;DR: This study demonstrates for the first time the generation of potent nasal mucosal and systemic immune responses using an i.n. delivered influenza vaccine powder and suggests an alternative approach to vaccination against influenza and other infectious diseases.
Journal ArticleDOI
Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine.
John A. Mikszta,John P. Dekker,Noel G. Harvey,Cheryl H. Dean,John M. Brittingham,Joanne Huang,Vincent J. Sullivan,Beverly Dyas,Chad J. Roy,Robert G. Ulrich +9 more
TL;DR: Overall, the results suggest rPA formulated with aluminum adjuvant and administered to the skin by a microneedle-based device is as efficacious as i.m. vaccination.
Journal ArticleDOI
Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine.
Joanne Huang,Ajit Joseph M. D'Souza,Jason B. Alarcon,John A. Mikszta,Brandi Ford,Matthew S. Ferriter,Michelle Evans,Todd Stewart,Kei Amemiya,Robert G. Ulrich,Vincent J. Sullivan +10 more
TL;DR: The preclinical feasibility of using a reconstituted powder F1-V formulation and microneedle-based intradermal delivery to provide protective immunity against plague in a mouse model is demonstrated and the results suggest that seroconversions against F1 may be a better predictor of protection against Y. pestis challenge than seroconversion against either F1 or V.
Journal ArticleDOI
Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine.
Ajit Joseph M. D'Souza,Kevin D. Mar,Joanne Huang,Sumit Majumdar,Brandi Ford,Beverly Dyas,Robert G. Ulrich,Vincent J. Sullivan +7 more
TL;DR: Deamidation of the recombinant protective antigen correlates with decreased effectiveness of the vaccine in protecting against infection by Bacillus anthracis and it is hypothesized that interactions of rPA with aluminum hydroxide gel are destabilizing and are the direct cause of reduced vaccine efficacy.